The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
On-treatment changes of plasma protein biomarkers in CALGB/SWOG 80405 (Alliance).
 
Ace Joseph Hatch
Employment - Alnylam (I); Pearl Therapeutics (I)
 
Fang-Shu Ou
No Relationships to Disclose
 
Tyler Zemla
No Relationships to Disclose
 
Mark D. Starr
No Relationships to Disclose
 
John C. Brady
No Relationships to Disclose
 
Yingmiao Liu
No Relationships to Disclose
 
Federico Innocenti
Patents, Royalties, Other Intellectual Property - Royalties from the Mayo Foundation on the UGT1A1 testing
 
Jeffrey A. Meyerhardt
Honoraria - Chugai Pharma; Ignyta
Consulting or Advisory Role - Genentech/Roche
 
Eileen Mary O'Reilly
Consulting or Advisory Role - 3DMedcare (I); Agios (I); Alignmed (I); Amgen (I); Antengene (I); Aptus Clinical; Aptus Clinical (I); ASLAN Pharmaceuticals (I); Astellas Pharma (I); AstraZeneca (I); Bayer (I); BeiGene (I); BiolineRx; Boston Scientific (I); Bridgebio (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); CARsgen Therapeutics (I); CASI Pharmaceuticals (I); CASI Pharmaceuticals (I); Celgene; Celgene (I); Celsion (I); Cipla (I); CytomX Therapeutics; Daiichi Sankyo (I); Debiopharm Group (I); Delcath Systems (I); Eisai (I); Exelixis (I); Genoscience Pharma (I); Gilead Sciences; Halozyme; Halozyme (I); Hengrui Medicine (I); Inovio Pharmaceuticals (I); Ipsen (I); Janssen; Jazz Pharmaceuticals (I); Kyowa Hakko Kirin (I); LAM Therapeutics (I); Lilly (I); Loxo; Merck (I); Merrimack; Minapharma (I); Newlink Genetics; Novella Clinical (I); Onxeo (I); PCI Biotech (I); Pfizer; Pharmacyclics; Pharmacyte Biotech; Pieris Pharmaceuticals; QED Therapeutics (I); RedHill Biopharma (I); Sanofi; Sanofi (I); Servier (I); Silenseed; Sillajen (I); Sirtex Medical (I); SOBI; Targovax; Tekmira (I); twoXAR; twoXAR (I); VAXIMM; Vicus Therapeutics (I); Yakult Pharmaceutical (I); Yakult Pharmaceutical (I); Yiviva (I)
Research Funding - Acta Biologica (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Halozyme (Inst); Mabvax (Inst); OncoQuest (Inst); OncoQuest (Inst); Roche (Inst)
 
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; Merck Serono; Roche
Consulting or Advisory Role - Bayer; Merck Serono; Pfizer; Roche
Travel, Accommodations, Expenses - Bayer; Merck Serono; Roche
 
Herbert Hurwitz
Honoraria - Genentech/Roche; Lilly/ImClone
Consulting or Advisory Role - Acceleron Pharma; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Incyte; Lilly; Novartis; OncoMed; TRACON Pharma
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Macrogenics (Inst); NCI (Inst); Novartis (Inst); Regeneron (Inst); TRACON Pharma (Inst)
 
Alan P. Venook
Consulting or Advisory Role - Bayer; Halozyme; Merrimack; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Serono (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Now-UptoDate for authoring and maintaining two chapters
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Genentech; Halozyme; Roche; Taiho Pharmaceutical
 
Andrew B. Nixon
Consulting or Advisory Role - Kanghong Pharma; Lilly; Pfizer
Research Funding - Acceleron Pharma; Amgen; AstraZeneca/MedImmune; Eureka Therapeutics; Genentech/Roche; Leadiant Biosciences; medpacto; Novartis; Seagen; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Patent (Inst); Patent Pending (Inst)
Travel, Accommodations, Expenses - TRACON Pharma